Stage 2 Stocks in Drug Manufacturers - General
9 US stocks in Drug Manufacturers - General are in Stage 2, the advancing phase of Weinstein's stage analysis. Listed below: those priced at $5 or more and trading at least $1 million a day on average, ranked by setup score and updated after every close (last close Oct 23, 2026).
| Stock | Close | 1D | Setup | Weeks in stage |
|---|---|---|---|---|
| AMGN Amgen Inc. | $439.26 | -1.79% | 7.8 | 16 |
| BIIB Biogen Inc. | $250.69 | -1.24% | 7.5 | 21 |
| LLY Eli Lilly and Company | $1,273.46 | -2.54% | 7.3 | 1 |
| ABBV AbbVie Inc. | $285.64 | +0.16% | 7.0 | 16 |
| OGN Organon & Co. | $13.75 | 0.00% | 6.5 | 23 |
| GILD Gilead Sciences, Inc. | $156.04 | -0.73% | 6.1 | 9 |
| PFE Pfizer, Inc. | $30.03 | -1.28% | 6.1 | 9 |
| MRK Merck & Company, Inc. | $145.27 | -1.34% | 5.3 | 17 |
| JNJ Johnson & Johnson | $263.81 | -1.42% | 4.3 | 16 |
Drug Manufacturers - General: quick answers
Which stocks in Drug Manufacturers - General are in an uptrend?
As of Oct 23, 2026, 9 US stocks in Drug Manufacturers - General are in Stage 2, the uptrend phase. The largest by market value are Eli Lilly, Johnson & Johnson, AbbVie, Merck and Amgen.
How many stocks in Drug Manufacturers - General are in Stage 2?
9 of the 21 stocks we track in Drug Manufacturers - General (42.9%) are in Stage 2. 1 is basing in Stage 1, 1 is topping in Stage 3 and 10 are in a Stage 4 downtrend. That share is unchanged over the last 20 sessions.
Which stocks in Drug Manufacturers - General entered Stage 2 recently?
1 stock entered Stage 2 in the last four weeks: Eli Lilly (its first week).
Daily screens
Every one recalculated after the close, with the exact criteria published on the page.
Stage 2 in other sectors & industries
US stocks in a confirmed uptrend (Stage 2, Weinstein’s advancing phase), grouped by sector and industry and ranked by setup score.